Beatrice M. Razzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beatrice M. Razzo has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Sperling
Dana-Farber Cancer Institute, Boston, MA
31 shared publications - Adriana Rossi
Icahn School of Medicine at Mount Sinai, New York, NY
31 shared publications - Aimaz Afrough
UT Southwestern Medical Center, Dallas, TX
31 shared publications - Alex Lieberman-Cribbin
Icahn School of Medicine at Mount Sinai, New York, USA
31 shared publications - Alfred L. Garfall
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
31 shared publications - Andre De Menezes Silva Corraes
Division of Hematology, Mayo Clinic, Rochester, Minnesota
31 shared publications
Latest Publications
- Open Access
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Relationship between PFS and time from last BCMA-directed therapy or serum ferritin
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Relationship between PFS and time from last BCMA-directed therapy or serum ferritin
- Open Access
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 6. Best Overall Response
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 6. Best Overall Response
- Open Access
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table S8: Multivariable regression for overall response
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table S8: Multivariable regression for overall response
- Open Access
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 2: Prior BCMA-directed therapy details
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 2: Prior BCMA-directed therapy details
- Open Access
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S11 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 11. Progression Free Survival Univariable and Multivariable Regression Analyses
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 11. Progression Free Survival Univariable and Multivariable Regression Analyses
- Open Access
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S13 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table S13: Progression-free survival univariable and multivariable regression analyses among patients with ≥VGPR
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S13 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table S13: Progression-free survival univariable and multivariable regression analyses among patients with ≥VGPR
- Open Access
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S9 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table S9: Univariable and multivariable regression for ≥VGPR
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table S9: Univariable and multivariable regression for ≥VGPR
- Open Access
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 1: Reasons for MajesTEC-1 ineligibility
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 1: Reasons for MajesTEC-1 ineligibility
- Open Access
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S12 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 12: Progression-free survival in prognostic subsets
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S12 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Supplemental Table 12: Progression-free survival in prognostic subsets